Bayesian Dose Response Analysis for Concave, Linear, and Convex - - PowerPoint PPT Presentation

bayesian dose response analysis for concave linear and
SMART_READER_LITE
LIVE PREVIEW

Bayesian Dose Response Analysis for Concave, Linear, and Convex - - PowerPoint PPT Presentation

Bayesian Dose Response Analysis for Concave, Linear, and Convex Monotone DR Curves Michel Friesenhahn and Paul Manser May 12, 2017 Confidential do not copy, distribute or use without prior written consent. Introduction 2 Who are we?


slide-1
SLIDE 1

Bayesian Dose Response Analysis for Concave, Linear, and Convex Monotone DR Curves

Michel Friesenhahn and Paul Manser May 12, 2017

Confidential — do not copy, distribute or use without prior written consent.

slide-2
SLIDE 2

2

Introduction

  • Who are we?

– Work at Genentech/Roche supporting early development non oncology – CNS (e.g. Alzheimer’s Disease, ALS, Pain) – Ophthalmology

  • Why do we worry about dose-response characterization?

– Safety and tolerability – Manufacturing (particularly for certain large molecules) – Minimize patient burden (e.g. frequency of dosing in ophthalmology)

  • We believe there are advantages to expressing uncertainty with Bayesian
  • methods. This can aid informed dose selection, but …

– How to select good priors, particularly when there is no prior information on shape? – Model selection? Model averaging?

  • Propose fitting a novel single family of concave, linear, and convex DR curves

– Has very geometrically interpretable parameters to aid in setting of priors – Reduces or eliminates need for model selection/averaging

Confidential — do not copy, distribute or use without prior written consent.

slide-3
SLIDE 3

3

Emax Model for Concave and Monotone DR

Confidential — do not copy, distribute or use without prior written consent.

slide-4
SLIDE 4

4

Re-parameterize

Confidential — do not copy, distribute or use without prior written consent.

Tested Dose Range Maximum treatment effect over tested dose range is:

slide-5
SLIDE 5

5

Re-parameterize

  • Maximal distance from Diagonal 1 is on

Diagonal 2 (Point B)

  • Tangent at point B is parallel to Diagonal 1

Confidential — do not copy, distribute or use without prior written consent.

Diagonal 1 Diagonal 2

slide-6
SLIDE 6

6

Lambda is Geometrically Interpretable

  • Re-parameterized Emax has directly interpretable parameters:

Confidential — do not copy, distribute or use without prior written consent.

slide-7
SLIDE 7

7

Also Spans Linear and Convex DR Curves

  • Natural mapping from to Concave, Linear and Convex DR curves
  • We call this a Concavex DR family
  • Could use MLE, perhaps with one further re-paramterization:

Confidential — do not copy, distribute or use without prior written consent.

slide-8
SLIDE 8

8

Setting Prior for λ

  • Theoretically-Motivated Non-informative

– Jeffrey’s Prior – Bornkamp’s Prior

  • Parameters considered as points in a metric space
  • Put uniform prior in the metric space to “spread out” the curves
  • Induces a prior on the parameters

– Approximations to Jeffrey’s and Bornkamp’s priors? Work in progress

  • Pragmatically-Motivated Non-informative

– Uniform – Beta(1/3,1/3)

  • Interpretability of λ should aid in setting prior when some information is available

Confidential — do not copy, distribute or use without prior written consent.

slide-9
SLIDE 9

9

Example for Trial in Knee Pain

Confidential — do not copy, distribute or use without prior written consent.

Concavex Priors

slide-10
SLIDE 10

10

Posterior Parameter Distributions

Confidential — do not copy, distribute or use without prior written consent.

Some text here

Efficacy Threshold C P(θ1 > C)

0 points 0.999 0.5 points 0.968 0.75 points 0.864 1 point 0.617

θ1 = 1.092 (0.570, 1.589)

slide-11
SLIDE 11

11

Basic Dose-Response Characterization

Confidential — do not copy, distribute or use without prior written consent.

slide-12
SLIDE 12

12

Characterizing Efficacy Risks vs Dose

Confidential — do not copy, distribute or use without prior written consent.

Target Efficacy Risks Suboptimal Efficacy Risks Ph 3 Efficacy Risks

slide-13
SLIDE 13

13

Standard Emax with Uniform Prior on ED50

Confidential — do not copy, distribute or use without prior written consent.

Concavex Priors Emax Priors

slide-14
SLIDE 14

14

Summary for Concavex Model

  • Single model family for concave, linear and convex dose response curves
  • Eliminates (or reduces) need for model selection or model averaging
  • Could be fit using maximum likelihood, but would suggest one further re-

parameterization of λ

  • We focus on efficacy risk profiles as a meaningful input to dose selection

– Most naturally obtained via Bayesian framework – Interpretability of Concave model aids in setting transparent priors

  • Development version of concavex R package currently available on GitHub

– github.com/paulmanser/concavex

Confidential — do not copy, distribute or use without prior written consent.